Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 7/20 | 0.34 |
| ▸ | NOS2 | P35228 | 4/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.33 |
| ▸ | NOS3 | P29474 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6805641 | 0.84 | CYP3A4 (0.47) | CYP3A4TSHRMAPK1TDP1TRPA1 | |
| SCHEMBL29854874 | 0.84 | CYP3A4 (0.57) | CYP3A4TSHRMAPK1TDP1TRPA1 | |
| SCHEMBL387552 | 0.84 | CYP3A4 (0.57) | CYP3A4TSHRMAPK1TDP1TRPA1 | |
| SCHEMBL842651 | 0.81 | MAPK1 (0.46) | CYP3A4TSHRMAPK1TDP1TRPA1 | |
| SCHEMBL7019980 | 0.81 | CYP3A4 (0.44) | CYP3A4TSHRMAPK1TDP1TRPA1 | |
| SCHEMBL27278789 | 0.81 | NOS1 (0.53) | CYP3A4TSHRMAPK1TDP1NOS1 | |
| SCHEMBL31182115 | 0.81 | CYP3A4 (0.44) | CYP3A4TSHRMAPK1TDP1TRPA1 | |
| SCHEMBL28845413 | 0.81 | NOS1 (0.49) | CYP3A4TSHRMAPK1TDP1TRPA1 | |
| SCHEMBL58461 | 0.81 | GABRA1 (0.50) | CYP3A4TSHRMAPK1TDP1TRPA1 | |
| SCHEMBL1357418 | 0.81 | CYP3A4 (0.44) | CYP3A4TSHRMAPK1TDP1TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222314-B2 | Phenyl isocyanate-based urethane acrylates, processes for producing and methods of using the same | BAYER MATERIALSCIENCE AG (DE) | 2012-07-17 | — | — | US | claimed |
| EP-2154129-A1 | Phenylisocyanate based urethanacrylate with high refraction index | Bayer MaterialScience AG (DE) | 2010-02-17 | — | — | EP | claimed |
| EP-2154128-A1 | Phenylisocyanate based urethanacrylates with high refraction index | Bayer MaterialScience AG (DE) | 2010-02-17 | — | — | EP | claimed |
| US-20100036013-A1 | PHENYL ISOCYANATE-BASED URETHANE ACRYLATES, PROCESSES FOR PRODUCING AND METHODS OF USING THE SAME | BAYER MATERIALSCIENCE AG (DE) | 2010-02-11 | — | — | US | claimed |
| US-20210155599-A1 | AROMATIC SUBSTITUTED ALKANE-CORE MONOMERS AND POLYMERS THEREOF FOR VOLUME BRAGG GRATINGS | META PLATFORMS TECHNOLOGIES, LLC | 2021-05-27 | — | — | US | disclosed |
| EP-2342249-B1 | PREPOLYMER-BASED POLYURETHANE FORMULATIONS FOR PRODUCING HOLOGRAPHIC MEDIA | COVESTRO DEUTSCHLAND AG (DE) | 2017-10-25 | — | — | EP | disclosed |
| EP-2396359-B1 | PHOTOPOLYMER COMPOUNDS AS COMPRESSIBLE FORMULATIONS | COVESTRO DEUTSCHLAND AG (DE) | 2017-09-27 | — | — | EP | disclosed |
| US-9454130-B2 | Photopolymer formulations having the adjustable mechanical modulus GUV | COVESTRO DEUTSCHLAND AG (DE) | 2016-09-27 | — | — | US | disclosed |
| CN-102792377-B | With adjustable mechanical modulus GuvPhotopolymer formulation of | BAYER MATERIALSCIENCE AG (DE) | 2016-06-01 | — | — | CN | disclosed |
| EP-2172502-B1 | POLYETHER-BASED POLYURETHANE FORMULATIONS FOR PRODUCING HOLOGRAPHIC MEDIA | COVESTRO DEUTSCHLAND AG (DE) | 2016-04-20 | — | — | EP | disclosed |
| CN-102667936-B | Method for producing holographic media | BAYER MATERIALSCIENCE AG (DE) | 2016-03-30 | — | — | CN | disclosed |
| US-9261778-B2 | Layer composite consisting of a photopolymer film and an adhesive layer | COVESTRO DEUTSCHLAND AG (DE) | 2016-02-16 | — | — | US | disclosed |
| US-6875760-B2 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2005-04-05 | — | — | US | disclosed |
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2003-11-27 | — | — | US | disclosed |
| US-6503949-B1 | Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity | NORO NORDISK A/S (DK) | 2003-01-07 | — | — | US | disclosed |
| EP-1183229-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000069810-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2000-11-23 | — | — | WO | disclosed |
| US-6096885-A | EXHIBIT AGONIST ACTIVITY FOR CCK-A RECEPTORS THEREBY ENABLING THEM TO MODULATE THE HORMONES GASTRIN AND CHOLECYSTOKININ IN MAMMALS. | GLAXO WELLCOME INC. (US) | 2000-08-01 | — | — | US | disclosed |
| EP-0785944-A1 | ACYL AMINO ACETAMIDE DERIVATIVES WITH AGONIST ACTIVITY FOR CCK-A RECEPTORS | GLAXO WELLCOME INC. (US) | 1997-07-30 | — | — | EP | disclosed |
| WO-1996011940-A1 | ACYL AMINO ACETAMIDE DERIVATIVES WITH AGONIST ACTIVITY FOR CCK-A RECEPTORS | GLAXO WELLCOME INC. (US) | 1996-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210155599-A1 | AROMATIC SUBSTITUTED ALKANE-CORE MONOMERS AND POLYMERS THEREOF FOR VOLUME BRAGG GRATINGS | SMAD2, ALK, SMAD3 | CYP3A4 3758/4885TSHR 4511/4885FOLH1 3347/4885 |
| US-20100036013-A1 | PHENYL ISOCYANATE-BASED URETHANE ACRYLATES, PROCESSES FOR PRODUCING AND METHODS OF USING THE SAME | GRHPR, CBR1, C1S | CYP3A4 783/4885TSHR 2098/4885FOLH1 4684/4885 |
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | CYP3A4 3264/4885TSHR 95/4885FOLH1 1731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.